Dr. Fartash Zahra, Dr Sana Shahid, Dr. Fraz Shakil
Objective: To investigate the effect of mefloquine on the visual condition. Patients and methods: The study confirmed 67 patients with weekly mefloquine therapy (for malaria prevention) for 1 year. Visual acuity, intraocular pressure (IOP), dilated posterior segment and visual field (VF) were taken to determine the ophthalmic condition. Results: Two of 69 patients had visual acuity pain and slight smearing. However, none of the shield’s changes in the retina, VF, fundus and anterior or posterior segment. The average age of cases is 43.58 (84.05%) are men and 11 (15.94%) are women. Conclusion: There is no risk of blindness after treatment with mefloquine for 1 year. In addition, more research is needed to assess the increased risk of long-term use. Key words: mefloquine, presbyopia, antimalarial drugs, retinal toxicity.